Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in Oregon: - Providence Newberg Medical Center — Newberg, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Oregon: - Research Site — Portland, Oregon
- Research Site — Portland, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Sponsor: AstraZeneca
NCT ID: NCT06346392
Sites in Oregon: - Research Site — Portland, Oregon
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gast…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221149
Sites in Oregon: - Oncology Associates Of Oregon, Pc — Eugene, Oregon
- Northwest Cancer Specialists, P.C. — Portland, Oregon
Phase 3 Recruiting Industry
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…
Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Sites in Oregon: - Research Facility — Portland, Oregon
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus tr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06731478
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
Phase 2 Recruiting Industry
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in Oregon: - Research Site — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Oregon: - Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
Phase 2 Recruiting Academic/Other
This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to nearby tissu…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT05705492
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
- Providence Oncology and Hematology Care Clinic - Westside — Portland, Oregon
- Providence St. Vincent Medical Center- Investigational Drug Services — Portland, Oregon
- Providence St. Vincent Medical Center — Portland, Oregon
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT06293898
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
Phase 1 Recruiting Industry
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Sponsor: Schrödinger, Inc.
NCT ID: NCT05544019
Sites in Oregon: - Oregon Health and Science University - Knight Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and t…
Sponsor: SillaJen, Inc.
NCT ID: NCT05768932
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered o…
Sponsor: MOMA Therapeutics
NCT ID: NCT06974110
Sites in Oregon: - Investigative Site #121 — Portland, Oregon
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
NA Recruiting Academic/Other
This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic te…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07091617
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
- Providence Hood River Memorial Hospital — Hood River, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oregon: - Massive Bio SYNERGY-AI site — Portland, Oregon
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Oregon: - Oregon Health Sciences University — Portland, Oregon